Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29870420 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL26299278 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661478 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661021 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL851826 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661377 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL101673 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL6555279 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL660625 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL16559904 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250144050-A1 | AMINOTHIOL-CONJUGATES, COMPOSITIONS, AND METHODS OF USE THEREOF | THE BURLINGTON HC RESEARCH GROUP, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-3604385-B1 | HETEROBIFUNCTIONAL MONODISPERSED POLYETHYLENE GLYCOL AND CONJUGATE USING THE SAME | NOF CORP (JP) | 2024-05-01 | — | — | EP | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| EP-3294714-B1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | NEKTAR THERAPEUTICS (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-2023028316-A1 | AMINOTHIOL-CONJUGATES, COMPOSITIONS, AND METHODS OF USE THEREOF | THE BURLINGTON HC RESEARCH GROUP, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-11419946-B2 | Heterobifunctional monodispersed polyethylene glycol and conjugate using same | NOF CORPORATION (JP) | 2022-08-23 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2021-09-07 | — | — | US | disclosed |
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | METHYLGENE INC. (CA) | 2014-03-20 | — | — | US | disclosed |
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | METHYLGENE INC. (CA) | 2014-03-20 | — | — | US | disclosed |
| US-20140057931-A1 | BUPRENORPHINE ANALOGS | PURDUE PHARMA L.P. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2619212-A1 | BUPRENORPHINE ANALOGS | Purdue Pharma L.P. (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130150441-A1 | Oligomer-Anticholinergic Agent Conjugates | NEKTAR THERAPEUTICS (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| WO-2012038813-A1 | BUPRENORPHINE ANALOGS | PURDUE PHARMA L.P. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2001034573-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | HDAC1, HDAC5, HDAC7 | USP2 3156/4885TSHR 4796/4885KDM4E 141/4885 |
| US-11419946-B2 | Heterobifunctional monodispersed polyethylene glycol and conjugate using same | FCGRT, L1CAM, CHRM1 | USP2 2126/4885TSHR 857/4885KDM4E 2006/4885 |
| US-20250144050-A1 | AMINOTHIOL-CONJUGATES, COMPOSITIONS, AND METHODS OF USE THEREOF | TIAL1, SLC7A11, MGMT | USP2 2215/4885TSHR 2033/4885KDM4E 4012/4885 |
| US-20130150441-A1 | Oligomer-Anticholinergic Agent Conjugates | CHRM3, CHRM4, CHRM5 | USP2 1545/4885TSHR 1812/4885KDM4E 3934/4885 |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | USP2 3328/4885TSHR 63/4885KDM4E 3952/4885 |
| US-20130096088-A1 | Inhibitors of Protein Tyrosine Kinase Activity | KDR, FLT1, FLT4 | USP2 1327/4885TSHR 766/4885KDM4E 3367/4885 |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRM1 | USP2 2879/4885TSHR 1145/4885KDM4E 2956/4885 |
| US-20140057931-A1 | BUPRENORPHINE ANALOGS | OPRL1, OPRD1, OPRK1 | USP2 4127/4885TSHR 960/4885KDM4E 3827/4885 |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | USP2 3328/4885TSHR 63/4885KDM4E 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.